Dose+
Overview
Dose+ is an AI-powered solution developed by MVision AI Oy, designed to support plan optimization for prostate and pelvic lymph node radiotherapy. Leveraging machine learning techniques, Dose+ generates patient-specific 3D dose predictions from CT images and structure sets, enabling radiation oncology professionals to plan more efficiently and consistently. The software creates clinically achievable VMAT (Volumetric Modulated Arc Therapy) dose distributions, which can be imported into any DICOM-compliant treatment planning system, providing a robust starting point for plan refinement. Dose+ aims to streamline radiotherapy workflows, enhance treatment quality, and reduce manual planning effort, ultimately leading to faster and more patient-focused care.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- AI-powered dose prediction for radiotherapy
- Patient-specific 3D dose estimates
- Supports plan optimization for prostate and pelvic lymph node radiotherapy
- Generates clinically achievable VMAT dose distributions
- Integrates with DICOM-compliant treatment planning systems
- Reduces manual workload by up to 70%
- Boosts planning consistency by up to 20%
- Achieves over 90% clinical acceptance rate
- Produces predictions in an average of 2 minutes
- Cloud-based solution with encrypted data transfer
Use Cases
- Radiotherapy treatment planning for prostate cancer
- Radiotherapy treatment planning for pelvic lymph node cancer
- Optimizing inverse planning in radiation therapy
- Streamlining radiotherapy workflows and increasing efficiency
- Enhancing treatment quality and consistency across planning scenarios
- Supporting clinical decision-making in radiation oncology
What Physicians Need to Know
Dose+ can significantly streamline your radiotherapy planning for prostate and pelvic lymph node cases by providing fast, personalized dose predictions. This can reduce manual workload and inter-planner variability, leading to more consistent and efficient treatment plans. While it offers a strong starting point, remember that all AI-generated dose predictions require review and validation by qualified professionals before clinical use. It's particularly valuable for complex cases, where it can help identify necessary trade-offs early in the planning process.
Dose+ is designed for seamless integration into existing clinical workflows. It is compatible with all DICOM-compliant treatment planning systems and operates as a cloud-based service, transferring data securely via DICOM. This vendor-neutral approach allows for smooth adoption without requiring extensive local tuning or customization.
Details
| Category | Oncology AI, Pharmacology & Dosing AI |
| Pricing | Unknown |
| Compliance | |
| BAA Available | Unknown |
| HIPAA Compliant | Unknown |
| FDA Status | Unknown |
| Integrations | |
| EHR | Not specified |
| Specialties | Oncology, Urology |
FDA clearance history
This product’s FDA authorization. From FDA’s list of AI-enabled medical devices; each number links to FDA’s record.
| Decision date | Number | Name as listed by FDA |
| 2025-09-04 | K250064 510(k) | Dose+ |
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate Dose+
Videos
Product demos, reviews, and walkthroughs for Dose+.
Dose+ for Radiotherapy: MVision AI Webinar on AI-Based Dose Prediction
MVision AI






